Related references
Note: Only part of the references are listed.Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
Rens Braster et al.
CANCERS (2021)
Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines
Neha Mehta-Shah et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Histopathologic Characterization of Mogamulizumab-associated Rash
Jennifer Y. Wang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines
Hiroaki Kamijo et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2017)
How I treat mycosis fungoides and Sezary syndrome
Sean Whittaker et al.
BLOOD (2016)
Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium
Elise A. Olsen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Systematic review of combination therapies for mycosis fungoides
Daniel Humme et al.
CANCER TREATMENT REVIEWS (2014)
Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Toshihiko Ishii et al.
CLINICAL CANCER RESEARCH (2010)
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
T Furlong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)